克隆演化解析揭示MSI2高水平促进T细胞急性淋巴细胞白血病化疗耐药
研究对配对诊断-复发T-ALL样本行单细胞RNA与配对TCR测序,揭示克隆转移与克隆漂移两种演化模式;靶向单细胞DNA测序证实两种模式并存,转录动态变化可使突变静态克隆产生化疗耐药;复发持续TCR克隆型中RNA结合蛋白MSI2表达显著上调,体内外功能研究提示MSI2通过转录后调控MYC促进T-ALL增殖和化疗耐药,提示MSI2为生物标志物和潜在治疗靶点。
要点
- 配对诊断-复发T-ALL单细胞测序揭示克隆转移与克隆漂移两种演化模式。
- 复发时持续存在的TCR克隆型中MSI2表达显著上调。
- MSI2通过转录后调控MYC促进T-ALL增殖与化疗耐药。
核心结论
- MSI2在复发持续TCR克隆型中显著上调,并通过转录后调控MYC促进T-ALL增殖和化疗耐药,提示其为生物标志物和潜在治疗靶点。
研究设计与样本
- 对配对诊断-复发T-ALL样本进行基于液滴的高通量5'单细胞RNA测序并配对T细胞受体(TCR)测序。
- 对配对诊断-复发T-ALL样本进行靶向单细胞DNA测序以验证克隆演化模式。
- 整合体外和体内功能研究探讨MSI2的作用。
主要发现
- 单细胞RNA与配对TCR测序揭示克隆转移和克隆漂移两种白血病演化模式。
- 靶向单细胞DNA测序进一步证实两种对比性克隆演化模式的存在。
- 动态转录变异可能使突变静态克隆演化出化疗耐药。
- 复发时持续TCR克隆型中RNA结合蛋白MSI2表达显著上调。
- 体外和体内功能研究提示MSI2通过转录后调控MYC促进T-ALL增殖和化疗耐药。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer with resistant clonal propagation in recurrence. We performed high-throughput droplet-based 5' single-cell RNA with paired T-cell receptor (TCR) sequencing of paired diagnosis-relapse (Dx_Rel) T-ALL samples to dissect the clonal diversities. Two leukemic evolutionary patterns, "clonal shift" and "clonal drift" were unveiled. Targeted single-cell DNA sequencing of paired Dx_Rel T-ALL samples further corroborated the existence of the 2 contrasting clonal evolution patterns, revealing that dynamic transcriptional variation might cause the mutationally static clones to evolve chemotherapy resistance. Analysis of commonly enriched drifted gene signatures showed expression of the RNA-binding protein MSI2 was significantly upregulated in the persistent TCR clonotypes at relapse. Integrated in vitro and in vivo functional studies suggested that MSI2 contributed to the proliferation of T-ALL and promoted chemotherapy resistance through the posttranscriptional regulation of MYC, pinpointing MSI2 as an informative biomarker and novel therapeutic target in T-ALL.
引用
- Zhang J, Duan Y, Wu P, et al. Clonal evolution dissection reveals that a high MSI2 level promotes chemoresistance in T-cell acute lymphoblastic leukemia. Blood. 2024. PMID: 37801708. doi:10.1182/blood.2023020490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。